复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02196 复星医药

未开盘 07-28 16:08:24

16.150

-0.050

-0.31%

最高16.320	最低15.940	成交量99.60万
今开16.270	昨收16.200	日振幅2.35%
总市值429.43亿	流通市值87.37亿	总股本26.59亿
成交额1,605万	换手率0.18%	流通股本5.41亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":16.15,"timestamp":1785226104005,"preClose":16.2,"halted":0,"volume":996000,"delay":0,"changeRate":-0.003086419753086464,"floatShares":540971500,"shares":2659000000,"eps":1.470831882694268,"marketStatus":"未开盘","change":-0.05,"latestTime":"07-28 16:08:24","open":16.27,"high":16.32,"low":15.94,"amount":16046299,"amplitude":0.023457,"askPrice":16.15,"askSize":1500,"bidPrice":16.12,"bidSize":3500,"shortable":3,"etf":0,"ttmEps":1.5169974736454166,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785288600000},"marketStatusCode":0,"adr":0,"listingDate":1351526400000,"exchange":"SEHK","adjPreClose":16.2,"dividendRate":0.027962,"openAndCloseTimeList":[[1785202200000,1785211200000],[1785214800000,1785225600000]],"volumeRatio":0.5225688350978994,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":22.62,"timestamp":1785222000000,"preClose":22.75,"halted":0,"volume":13716400,"delay":0,"premium":"-38.35"}},"requestUrl":"/m/hq/s/02196","defaultTab":"news","newsList":[{"id":"2654305050","title":"复星医药：DM1001制剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654305050","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654305050?lang=zh_cn&edition=full","pubTime":"2026-07-26 09:24","pubTimestamp":1785029040,"startTime":"0","endTime":"0","summary":"　　复星医药发布公告，近日，上海复星医药（集团）股份有限公司控股子公司复星万邦（江苏）医药集团有限公司收到国家药品监督管理局关于同意DM1001制剂用于治疗成人特发性帕金森病的体征和症状开展临床试验的批准。复星万邦拟于条件具备后于中国境内开展该药品的I期临床试验。截至2026年6月，本集团现阶段针对该药品的累计研发投入约为人民币695万元。　　根据IQVIA CHPA最新数据，2025年，相同化合物药品于中国境内的销售额约为人民币3.75亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-07-26/doc-inikawyr0992109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0060","MDTX","BK0196","IBBQ","BK1593","600196","BK0096","BK0187","BK0175","BK0028","BK1515","02196","BK0239","BK1191","BK0183","BK0012","BK0188","BMED","IBBJ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654052696","title":"每周股票复盘：复星医药（600196）控股子公司帕金森病新药获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2654052696","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654052696?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:14","pubTimestamp":1784999651,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，复星医药报收于22.67元，较上周的23.4元下跌3.12%。本周关注点来自公司公告汇总：复星医药控股子公司帕金森病治疗新药获临床试验批准。复星医药关于控股子公司药品获临床试验批准的公告上海复星医药（集团）股份有限公司控股子公司复星万邦（江苏）医药集团有限公司收到国家药监局批准，同意DM1001制剂用于治疗成人特发性帕金森病的体征和症状开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK1515","BK0060","600196","02196","BK0188","BK0096","BK0239","BK1191","BK0187","BK0175","BK0183","BK0196","BK1593","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653038365","title":"复星医药（600196）披露控股子公司药品获临床试验批准公告，7月24日股价下跌4.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653038365","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653038365?lang=zh_cn&edition=full","pubTime":"2026-07-24 22:04","pubTimestamp":1784901855,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，复星医药报收于22.67元，较前一交易日下跌4.39%，最新总市值为605.39亿元。近日，复星医药发布关于控股子公司药品获临床试验批准的公告。公告显示，公司控股子公司复星万邦（江苏）医药集团有限公司收到国家药监局批准，同意DM1001制剂用于治疗成人特发性帕金森病的体征和症状开展临床试验。复星万邦拟于条件具备后在中国境内开展I期临床试验。该药品为化学药物，截至2026年6月，本集团累计研发投入约人民币695万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400041476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0012","BK0060","BK0239","BK0175","BK0028","BK0096","BK1593","BK1515","BK0183","02196","BK1191","600196","BK0187","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170761159","title":"复星医药控股子公司获批开展DM1001一期开发 用于治疗成人特发性帕金森病","url":"https://stock-news.laohu8.com/highlight/detail?id=1170761159","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170761159?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:22","pubTimestamp":1784884974,"startTime":"0","endTime":"0","summary":"2026年7月24日，复星医药公告，其控股子公司复星万邦（江苏）医药集团有限公司已收到国家药品监督管理局关于同意DM1001制剂用于治疗成人特发性帕金森病体征和症状的临床试验批准。复星万邦计划在条件具备后于中国境内启动I期临床试验。公司提示，DM1001仍需在中国开展后续临床研究并通过药品审评部门审批后方可上市，药物研发存在安全性、有效性等不确定性风险，投资者需关注相关风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653610700","title":"复星医药(600196.SH)子公司DM1001制剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2653610700","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653610700?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:48","pubTimestamp":1784882924,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，近日，公司控股子公司复星万邦(江苏)医药集团有限公司(简称“复星万邦”)收到国家药品监督管理局关于同意DM1001制剂用于治疗成人特发性帕金森病的体征和症状开展临床试验的批准。复星万邦拟于条件具备后于中国境内开展该药品的I期临床试验。该药品系化学药物。根据IQVIA CHPA最新数据，2025年，相同化合物药品于中国境内的销售额约为3.75亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK1593","600196","BK1515","BK0239","BK0188","IBBJ","BK0060","BK0183","BK1191","BK0196","BK0012","PSYK","BK0028","BK0096","BK0175","BMED","IBBQ","MDTX","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653766845","title":"复星医药（600196）披露股东部分股份解除质押公告，7月22日股价上涨1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653766845","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653766845?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:21","pubTimestamp":1784730076,"startTime":"0","endTime":"0","summary":"截至2026年7月22日收盘，复星医药报收于23.97元，较前一交易日上涨1.18%，最新总市值为640.1亿元。该股当日开盘23.5元，最高24.23元，最低23.43元，成交额达7.05亿元，换手率为1.39%。近日，复星医药发布关于股东部分股份解除质押的公告。截至2026年7月21日收市，复星高科技持有复星医药961,424,455股股份，约占公司总股本的36.00%。复星高科技及其一致行动人合计持有公司股份967,812,180股，占公司总股本的36.24%，本次解除质押后累计质押股份余额为523,275,000股，占其合计持股的54.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072200047443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0028","BK0060","BK0239","600196","BK0012","BK0175","BK1515","BK0183","BK0196","BK0187","BK1593","BK0188","02196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135174307","title":"复星医药：复星高科技解除6900万股质押 仍有5.23亿股处于质押状态","url":"https://stock-news.laohu8.com/highlight/detail?id=1135174307","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135174307?lang=zh_cn&edition=full","pubTime":"2026-07-22 17:15","pubTimestamp":1784711754,"startTime":"0","endTime":"0","summary":"2026年7月22日，复星医药公告称，公司控股股东上海复星高科技（集团）有限公司已于2026年7月21日解除所持公司部分A股质押，涉及股份69,000,000股，占其持股数量的7.18%，占公司当日收市总股本的2.58%。本次解除后，上述主体合计质押股份余额同为523,275,000股，占其合计持股数量的54.07%。复星医药表示，将继续关注控股股东及其一致行动人股份质押情况，并按照相关法律法规及上市规则及时披露后续进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653753685","title":"复星医药：控股股东复星高科技解除质押6900万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653753685","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653753685?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:31","pubTimestamp":1784709077,"startTime":"0","endTime":"0","summary":"7月22日，复星医药公告，公司于2026年7月22日接到控股股东上海复星高科技（集团）有限公司通知，其已将所持有的公司6900.00万股A股办理解除质押手续，解除质押时间为2026年7月21日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817298873.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817298873.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0183","BK0060","BK0187","BK0196","BK0239","BK0096","BK1593","BK1515","BK0188","BK0028","600196","BK0012","BK1191","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652294063","title":"复星医药连续四年登榜“中国卓越管理公司”","url":"https://stock-news.laohu8.com/highlight/detail?id=2652294063","media":"复星医药官微","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652294063?lang=zh_cn&edition=full","pubTime":"2026-07-20 17:08","pubTimestamp":1784538480,"startTime":"0","endTime":"0","summary":"2026年7月17日，由德勤中国、香港科技大学商学院和《哈佛商业评论》中文版联合主办的第八届中国卓越管理公司项目评选揭晓。复星医药连续四年登榜“中国卓越管理公司”榜单 ，再度彰显公司在战略前瞻性、创新执行力、全球化治理及财务健康度等方面的综合管理实力。复星医药连续四年获得BMC权威认可，印证了公司在管理体系与战略执行能力。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-20/doc-iniimzhh5008087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0096","BK0196","BK1593","BK1191","BK0187","BK0183","BK0175","BK0188","BK0239","600196","BK0060","BK0028","BK0012","BK1515","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237560","title":"每周股票复盘：复星医药（600196）股东质押5.92亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652237560?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:12","pubTimestamp":1784394730,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，复星医药报收于23.4元，较上周的23.45元下跌0.21%。本周，复星医药7月16日盘中最高价报25.18元。本次质押后，复星高科技累计质押公司股份592,275,000股，约占公司总股本的22.18%。复星医药2025年年度A股权益分派实施公告：本次权益分派每股现金红利0.39元（税前），以扣除已回购股份后的2,639,554,073股为基数，预计派发现金红利1,029,426,088.47元（税前）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0012","BK0196","BK0028","BK0175","BK0187","BK0239","BK0096","02196","BK1515","BK1593","600196","BK1191","BK0183","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651440775","title":"复星医药（600196）披露2025年年度A股权益分派实施公告，7月16日股价下跌0.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651440775","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651440775?lang=zh_cn&edition=full","pubTime":"2026-07-16 22:20","pubTimestamp":1784211628,"startTime":"0","endTime":"0","summary":"截至2026年7月16日收盘，复星医药报收于24.71元，较前一交易日下跌0.52%，最新总市值为659.86亿元。近日，上海复星医药（集团）股份有限公司发布《2025年年度A股权益分派实施公告》。公告显示，本次权益分派每股现金红利0.39元（税前），股权登记日为2026年7月24日，除权（息）日和现金红利发放日均为2026年7月27日。本次权益分派以总股本扣除已回购股份后的2,639,554,073股为基数，预计派发现金红利1,029,426,088.47元（税前）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600040175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0028","BK0060","BK0239","600196","BK0012","BK0175","BK1515","BK0183","BK0196","399300","BK0187","BK1593","BK0188","02196","BK1191","159982"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181593948","title":"复星医药发布2025年度A股分红实施公告：每股派现0.39元，7月27日发放","url":"https://stock-news.laohu8.com/highlight/detail?id=1181593948","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181593948?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:15","pubTimestamp":1784196950,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司于2026年7月17日披露《2025年年度A股权益分派实施公告》。公司将按照2025年度股东大会审议通过的利润分配方案，向A股股东派发现金红利，核心安排如下：。——每股派发现金红利人民币0.39元（税前）。——以截至2026年7月24日收市后在中国证券登记结算有限责任公司上海分公司登记在册的可参与分配的A股股东为对象。复星医药提示投资者关注相关时间节点，并依照自身情况办理税务事项。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171903723","title":"复星医药子公司FXr0906高甘油三酯血症治疗药物获中国NMPA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1171903723","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171903723?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:16","pubTimestamp":1784110587,"startTime":"0","endTime":"0","summary":"复星医药旗下子公司研发的FXr0906，一种用于治疗高甘油三酯血症的药物，已正式获得中国国家药品监督管理局的临床试验批准。这一进展标志着该药物向临床应用迈出了关键一步，为相关患者群体带来了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0175","BK0196","BK0028","BK0012","BK0183","BK0187","BK0239","BK0188","BK1191","02196","BK0096","BK1593","BK1515","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651454391","title":"复星医药(02196.HK)：FXR0906 注射液用于治疗高甘油三酯血症获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2651454391","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651454391?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:15","pubTimestamp":1784110556,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1593","BK1515","02196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651592034","title":"复星医药(600196.SH)子公司FXR0906注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651592034","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651592034?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:45","pubTimestamp":1784108751,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司复星医药产业发展(深圳)有限公司收到国家药品监督管理局关于同意FXR0906注射液用于治疗高甘油三酯血症开展临床试验的批准。复星医药(深圳)拟于条件具备后于中国境内1开展该药物的I期临床研究。FXR0906通过RNA干扰技术、沉默APOC3基因表达，降低血清甘油三酯水平，从而实现对高甘油三酯血症的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK1191","BK0096","BK0188","BK0196","BK0012","IBBQ","BK0060","BK1593","02196","600196","BMED","BK0183","BK0028","BK0239","BK0187","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651459437","title":"复星医药：控股股东质押4700万股，累计质押超六成持股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651459437","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651459437?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:33","pubTimestamp":1784107980,"startTime":"0","endTime":"0","summary":"7月15日，复星医药（600196/02196）发布公告，控股股东复星高科技将其持有的4700万股办理质押，占其所持股份的4.89%及公司总股本的1.76%。截至公告披露日，复星高科技累计质押股份为5.92亿股，占其所持股份的61.60%及公司总股本的22.18%。2026年一季度，复星医药实现收入100.73亿元，归母净利润8.71亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607153807542370.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607153807542370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0096","BK1191","BK0012","BK0060","BK0183","BK1515","BK0239","600196","BK0187","02196","BK0188","BK0196","BK1593","BK0175","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651289171","title":"【券商聚焦】中信证券：预计美妆行业在次季延续低速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2651289171","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651289171?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:55","pubTimestamp":1783990545,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，22026Q2，预计美妆行业在需求疲弱、流量成本走高、内容运营压力加大的背景下延续低速增长；结构性进一步分化，国际高端品牌销售反弹，本土大众、中端定位品牌承压；毛戈平、林清轩延续高增长，巨子生物、贝泰妮、敷尔佳销售底部回升。2026Q2，医美板块上游产品供给增加，竞争延续较高强度，四环医药受益于自主产品上市继续提升市场份额。估值已充分反映当前的经营压力且已严重低估，静候基本面改善和估值回升。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985765","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02373","LU0405327494.USD","BK0188","00460","06030","BK0012","BK0028","LU1064130708.USD","BK1521","BK1600","LU2289578879.USD","LU1064131003.USD","BK1585","LU0405327148.USD","BK1207","LU1255011170.USD","LU1655091616.SGD","LU2495084118.USD","BK0196","LU1997244956.HKD","BK0276","BK1511","600030","HK0000165453.HKD","01530","BK1516","LU1997245094.SGD","LU1720050803.USD","LU2148510915.USD","LU1794554557.SGD","BK1564","LU2488822045.USD","LU1580142542.USD","KCE","BK1147","BK1587","02196","LU1997245177.USD","01696","BK0183","BK1583","BK1161","BK1215","02367","06699","BK1515","SG9999004311.SGD","LU1328615791.USD","BK1100","02138"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650279151","title":"每周股票复盘：复星医药（600196）HLX37联合用药方案获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2650279151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650279151?lang=zh_cn&edition=full","pubTime":"2026-07-12 01:31","pubTimestamp":1783791067,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，复星医药报收于23.45元，较上周的23.29元上涨0.69%。本周，复星医药7月6日盘中最高价报24.24元。该联合用药方案在全球范围内尚无同类产品获批上市。HLX37为抗PD-L1与抗VEGF双特异性抗体，HLX43为靶向PD-L1的抗体偶联药物。目前相关药品均处于临床试验阶段，后续需经国家药品审评部门审批方可上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1593","BK0183","BK1191","600196","BK0196","BK0012","BK0188","BK0028","BK0096","BK0060","BK0175","02196","BK0187","BK1515","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650573135","title":"复星医药（600196）披露控股子公司药品获临床试验批准公告，7月10日股价上涨2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650573135","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650573135?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:10","pubTimestamp":1783692626,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，复星医药报收于23.45元，较前一交易日上涨2.18%，最新总市值为626.22亿元。近日，上海复星医药（集团）股份有限公司披露公告，其控股子公司复宏汉霖收到国家药品监督管理局批准，同意其自主研发的HLX37注射液联合化疗或HLX43用于晚期/转移性实体瘤治疗开展Ⅰ期临床试验。该联合用药方案在全球范围内尚无同类产品获批上市。目前相关药品均处于临床试验阶段，后续需经国家药品审评部门审批方可上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0060","BK0183","BK0187","BK0175","BK1593","600196","BK1191","BK0196","BK1515","BK0239","BK0028","BK0188","BK0096","02196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650869701","title":"复星医药最新公告：控股子公司HLX37联合HLX43获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2650869701","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650869701?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:21","pubTimestamp":1783675314,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖收到国家药监局批准，同意HLX37注射液联合化疗或HLX43用于晚期/转移性实体瘤开展Ⅰ期临床试验。截至公告日，全球尚无同类联合用药获批上市，该治疗方案累计研发投入约859万元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000031047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK1191","BK0012","BK0060","BK0183","BK1515","BK0239","600196","BK0187","02196","BK0188","BK0196","BK1593","BK0175","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fosunpharma.com","stockEarnings":[{"period":"1week","weight":-0.0194},{"period":"1month","weight":0.1016},{"period":"3month","weight":-0.1527},{"period":"6month","weight":-0.2093},{"period":"1year","weight":-0.1287},{"period":"ytd","weight":-0.1514}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.1164},{"period":"3month","weight":-0.0307},{"period":"6month","weight":-0.095},{"period":"1year","weight":-0.0098},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复星医药（集团）股份有限公司是一家主要从事医药产品研发、制造与销售的中国公司。该公司通过五个分部开展业务。制药分部主要从事药品的研发、生产和销售。医疗器械与医学诊断分部主要从事医疗器械和诊断产品的研发、生产和销售。医疗健康服务分部主要从事提供医疗健康服务及医院管理。医药分销和零售分部主要从事医药、器械分销和零售。 该公司还运营其他分部。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044495},{"month":2,"riseRate":0.714286,"avgChangeRate":0.036179},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044259},{"month":4,"riseRate":0.357143,"avgChangeRate":0.026},{"month":5,"riseRate":0.428571,"avgChangeRate":0.024935},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.032656},{"month":7,"riseRate":0.642857,"avgChangeRate":0.032619},{"month":8,"riseRate":0.307692,"avgChangeRate":-0.041663},{"month":9,"riseRate":0.461538,"avgChangeRate":0.011613},{"month":10,"riseRate":0.461538,"avgChangeRate":0.020365},{"month":11,"riseRate":0.428571,"avgChangeRate":0.034477},{"month":12,"riseRate":0.428571,"avgChangeRate":0.015129}],"exchange":"SEHK","name":"复星医药","nameEN":"FOSUN PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,02196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(02196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(02196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}